Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
复制标题
Chadox1 NCOV-19（AZD1222）疫苗对巴西循环的SARS-COV-2谱系的功效。
DOI：
10.1038/s41467-021-25982-w
复制
发表时间：
2021-10-06
影响因子：
16.6
通讯作者：
Oxford COVID Vaccine Trial Team
中科院分区：
文献类型：
--
作者：
Clemens SAC;Folegatti PM;Emary KRW;Weckx LY;Ratcliff J;Bibi S;De Almeida Mendes AV;Milan EP;Pittella A;Schwarzbold AV;Sprinz E;Aley PK;Bonsall D;Fraser C;Fuskova M;Gilbert SC;Jenkin D;Kelly S;Kerridge S;Lambe T;Marchevsky NG;Mujadidi YF;Plested E;Ramasamy MN;Simmonds P;Golubchik T;Voysey M;Pollard AJ;AMPHEUS Project;Oxford COVID Vaccine Trial Team
几种COVID-19疫苗在临床试验中显示出良好的疗效，但疫苗对不同变种的疗效仍存在不确定性。在此，我们在巴西一项III期随机试验（试验注册ISRCTN 89951424）的事后探索性分析中研究了ChAdOx 1 nCoV-19（AZD 1222）对症状性COVID-19的疗效。在有症状的参与者中，通过PCR检测鼻拭子和咽拭子。对拭子进行测序和基因分型，以确定研究期间传播的SARS-CoV-2谱系。在153例病例中评估了对Zeta（P.2）变体引起的任何症状性COVID-19的保护，疫苗有效性（VE）为69%（95% CI 55，78）。B.1.1.28发生49例，VE为73%（46，86）。Gamma（P.1）变体在试验后期出现，可用于分析的病例较少（N = 18）。VE为64%（-2，87）。ChAdOx 1 nCoV-19提供了95%的保护（95% CI 61%，99%），防止因COVID-19住院治疗。总之，我们报告说，ChAdOx 1 nCoV-19保护巴西的新变种，尽管存在刺突蛋白突变E484 K。新出现的SARS-CoV-2变种引起了人们对疫苗效率的担忧。在本文中，作者对巴西的ChAdOx 1 nCoV-19（AZD 1222）疫苗试验进行了事后分析，并提供了对Zeta（P.2）和其他变体引起的症状性COVID-19的有效性。
Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in a post-hoc exploratory analysis of a Phase 3 randomised trial in Brazil (trial registration ISRCTN89951424). Nose and throat swabs were tested by PCR in symptomatic participants. Sequencing and genotyping of swabs were performed to determine the lineages of SARS-CoV-2 circulating during the study. Protection against any symptomatic COVID-19 caused by the Zeta (P.2) variant was assessed in 153 cases with vaccine efficacy (VE) of 69% (95% CI 55, 78). 49 cases of B.1.1.28 occurred and VE was 73% (46, 86). The Gamma (P.1) variant arose later in the trial and fewer cases (N = 18) were available for analysis. VE was 64% (−2, 87). ChAdOx1 nCoV-19 provided 95% protection (95% CI 61%, 99%) against hospitalisation due to COVID-19. In summary, we report that ChAdOx1 nCoV-19 protects against emerging variants in Brazil despite the presence of the spike protein mutation E484K. Emerging variants of SARS-CoV-2 raise concerns about vaccine efficiency. Here, the authors present a post-hoc analysis for the ChAdOx1 nCoV-19 (AZD1222) vaccine trial in Brazil and provide efficacy against symptomatic COVID-19 caused by the Zeta (P.2) and other variants.
登录
查看更多内容
影响因子：
64.5
作者：
Hoffmann M;Arora P;Groß R;Seidel A;Hörnich BF;Hahn AS;Krüger N;Graichen L;Hofmann-Winkler H;Kempf A;Winkler MS;Schulz S;Jäck HM;Jahrsdörfer B;Schrezenmeier H;Müller M;Kleger A;Münch J;Pöhlmann S
通讯作者：
Pöhlmann S
整合素结合肽 ATN-161，作为 SARS-CoV-2 感染的新疗法。
DOI：
10.1016/j.jacbts.2020.10.003
发表时间：
2021-01
期刊：
JACC. Basic to translational science
影响因子：
--
作者：
Beddingfield BJ;Iwanaga N;Chapagain PP;Zheng W;Roy CJ;Hu TY;Kolls JK;Bix GJ
通讯作者：
Bix GJ
DOI：
10.1056/nejmoa2102214
发表时间：
2021-05-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Madhi SA;Baillie V;Cutland CL;Voysey M;Koen AL;Fairlie L;Padayachee SD;Dheda K;Barnabas SL;Bhorat QE;Briner C;Kwatra G;Ahmed K;Aley P;Bhikha S;Bhiman JN;Bhorat AE;du Plessis J;Esmail A;Groenewald M;Horne E;Hwa SH;Jose A;Lambe T;Laubscher M;Malahleha M;Masenya M;Masilela M;McKenzie S;Molapo K;Moultrie A;Oelofse S;Patel F;Pillay S;Rhead S;Rodel H;Rossouw L;Taoushanis C;Tegally H;Thombrayil A;van Eck S;Wibmer CK;Durham NM;Kelly EJ;Villafana TL;Gilbert S;Pollard AJ;de Oliveira T;Moore PL;Sigal A;Izu A;NGS-SA Group;Wits-VIDA COVID Group
通讯作者：
Wits-VIDA COVID Group
SARS-COV-2内部多样性和传播。
DOI：
10.1126/science.abg0821
发表时间：
2021-04-16
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Lythgoe KA;Hall M;Ferretti L;de Cesare M;MacIntyre-Cockett G;Trebes A;Andersson M;Otecko N;Wise EL;Moore N;Lynch J;Kidd S;Cortes N;Mori M;Williams R;Vernet G;Justice A;Green A;Nicholls SM;Ansari MA;Abeler-Dörner L;Moore CE;Peto TEA;Eyre DW;Shaw R;Simmonds P;Buck D;Todd JA;Oxford Virus Sequencing Analysis Group (OVSG);Connor TR;Ashraf S;da Silva Filipe A;Shepherd J;Thomson EC;COVID-19 Genomics UK (COG-UK) Consortium;Bonsall D;Fraser C;Golubchik T
通讯作者：
Golubchik T
影响因子：
10.7
作者：
Nguyen LT;Schmidt HA;von Haeseler A;Minh BQ
通讯作者：
Minh BQ